Medigen Vaccine Biologics Corp. (MVC), a subsidiary of Medigen Biotechnology Corp. (Medigen), has signed an alliance agreement for biosimilar drug development with the Utrecht Centre of for Affordable Biotherapeutics (UCAB) in the Netherlands, Europe-based MABXIENCE, Middle East-based SPIMACO, and South America-based LIBBS. The alliance aims to develop a biosimilar product for the prevention of respiratory syncytial virus (RSV) infections in infants and young children. 

This international alliance is coordinated by UCAB, a globally renowned non-profit biopharmaceutical research organization, which will oversee the project and lead the clinical trials. MABXIENCE, with its expertise in protein-based drug manufacturing, will be responsible for production, manufacturing, and subsequent technology transfer to ensure product quality. Alliance members will jointly share research and development costs, as well as clinical outcomes, while applying for marketing approvals, production, and commercialization in their respective regional markets. Under this agreement, MVC will hold exclusive rights for sales, technology transfer, and manufacturing in Taiwan and major Asian countries. MVC will also participate in research and clinical trial activities within the alliance and transfer biosimilar manufacturing technology to its biopharmaceutical facility in Hsinchu Biomedical Park. 

Through this collaboration, MVC not only expands beyond its existing cell culture-based vaccine business but also enters the protein drug development and manufacturing sector, strengthening its overall positioning in the biopharmaceutical field. Furthermore, strategic alliances with international research institutions and major pharmaceutical companies are expected to enhance MVC's R&D and production capacity, while integrating the Company into the mainstream global pharmaceutical community. 

Related Information: 

1.UCAB Research Center 
2.MABXIENCE 
3.SPIMACO 
4.LIBBS